Curated News
By: NewsRamp Editorial Staff
September 29, 2026
Nutriband CEO Featured in Opioid Crisis Documentary
TLDR
- Nutriband CEO showcases AVERSA abuse-deterrent platform in new documentary, positioning NTRB as a leader in opioid crisis solutions.
- Nutriband's AVERSA technology integrates into transdermal patches to deter abuse, misuse, diversion, and accidental exposure of high-risk medications.
- Nutriband's AVERSA platform aims to reduce opioid abuse while preserving patient access, potentially improving lives and addressing a public health crisis.
- A new documentary by Nick Shirley explores the opioid crisis and features Nutriband CEO discussing innovative abuse-deterrent technology.
Impact - Why it Matters
This news matters because the opioid crisis continues to devastate communities across the United States, with abuse and accidental exposure to high-risk medications like fentanyl claiming thousands of lives annually. Nutriband's AVERSA™ abuse-deterrent technology represents a potential breakthrough in preventing the misuse and diversion of transdermal patches, which are particularly vulnerable to abuse due to their concentrated drug content. By participating in this documentary, CEO Gareth Sheridan brings attention to innovative pharmaceutical solutions that could help mitigate the crisis while ensuring that patients with legitimate medical needs retain access to essential pain therapies. As the company advances its lead product—an abuse-deterrent fentanyl patch—investors and healthcare stakeholders should monitor its progress, as successful commercialization could significantly impact public health and set a new standard for safer transdermal drug delivery.
Summary
Nutriband (NASDAQ: NTRB) has announced that its CEO, Gareth Sheridan, is featured in a new documentary by independent journalist and filmmaker Nick Shirley that examines the opioid crisis in the United States. In the documentary, Sheridan discusses pharmaceutical innovation and technologies, including the Nutriband AVERSA™ abuse-deterrent platform, which is designed to reduce the risk of abuse, misuse, diversion, and accidental exposure associated with high-risk medications while preserving access for patients with legitimate medical needs.
Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is an abuse-deterrent fentanyl patch incorporating its AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. For more information, visit the company’s website at www.nutriband.com. The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB.
The announcement was distributed through InvestorWire, a specialized communications platform with a focus on advanced wire-grade press release syndication. InvestorWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband CEO Featured in Opioid Crisis Documentary
